No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Prelude Announces Presentations at 2025 AACR Annual Meeting
Prelude Therapeutics: Solid Financial Position and Promising Clinical Catalysts Amidst Risks
Prelude Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Krishna Vaddi Bought 4.3% More Shares In Prelude Therapeutics
Prelude Therapeutics CEO Makes Bold Stock Purchase